{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:19:15Z","timestamp":1768439955670,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"DOI":"10.7759\/cureus.101525","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:17:22Z","timestamp":1768403842000},"source":"Crossref","is-referenced-by-count":0,"title":["Circulating Orexin-A Levels in Patients With Schizophrenia, Bipolar Disorder, and Major Depressive Disorder: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Shatha","family":"Almahwzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Ghabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadha","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Alsolami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashid","family":"Juma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lojean","family":"Althobyane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manar","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshal","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21326","article-title":"The hypocretin\/orexin system: an increasingly important role in neuropsychiatry","volume":"35","author":"Chen Q","year":"2015","unstructured":"Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin\/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev. 2015, 35:152-97. 10.1002\/med.21326","journal-title":"Med Res Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell TE","year":"2011","unstructured":"Scammell TE, Winrow CJ. Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2011, 51:243-66. 10.1146\/annurev-pharmtox-010510-100528","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot E","year":"2002","unstructured":"Mignot E, Lammers GJ, Ripley B, et al.. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002, 59:1553-62. 10.1001\/archneur.59.10.1553","journal-title":"Arch Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/srep27974","article-title":"Proteomic analysis of egg white heparin-binding proteins: towards the identification of natural antibacterial molecules","volume":"6","author":"Guyot N","year":"2016","unstructured":"Guyot N, Labas V, Harichaux G, et al.. Proteomic analysis of egg white heparin-binding proteins: towards the identification of natural antibacterial molecules. Sci Rep. 2016, 6:27974. 10.1038\/srep27974","journal-title":"Sci Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12130","article-title":"CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?","volume":"23","author":"Liguori C","year":"2014","unstructured":"Liguori C, Placidi F, Albanese M, et al.. CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. J Sleep Res. 2014, 23:420-4. 10.1111\/jsr.12130","journal-title":"J Sleep Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063136","article-title":"Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease","volume":"8","author":"Schmidt FM","year":"2013","unstructured":"Schmidt FM, Kratzsch J, Gertz HJ, et al.. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS One. 2013, 8:e63136. 10.1371\/journal.pone.0063136","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2004.05.003","article-title":"Genotype-dependent effect of ACTH1-24 on grooming and yawning in two inbred strains of rats","volume":"38","author":"Eguibar JR","year":"2004","unstructured":"Eguibar JR, Barajas M, Moyaho A. Genotype-dependent effect of ACTH1-24 on grooming and yawning in two inbred strains of rats. Neuropeptides. 2004, 38:283-8. 10.1016\/j.npep.2004.05.003","journal-title":"Neuropeptides"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2008.09.042","article-title":"I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation","volume":"157","author":"Ito N","year":"2008","unstructured":"Ito N, Yabe T, Gamo Y, et al.. I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience. 2008, 157:720-32. 10.1016\/j.neuroscience.2008.09.042","journal-title":"Neuroscience"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2010.10.033","article-title":"Association between major mood disorders and the hypocretin receptor 1 gene","volume":"130","author":"Rainero I","year":"2011","unstructured":"Rainero I, Ostacoli L, Rubino E, et al.. Association between major mood disorders and the hypocretin receptor 1 gene. J Affect Disord. 2011, 130:487-91. 10.1016\/j.jad.2010.10.033","journal-title":"J Affect Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2007.01.005","article-title":"Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder","volume":"17","author":"Brundin L","year":"2007","unstructured":"Brundin L, Bj\u00f6rkqvist M, Peters\u00e9n A, Tr\u00e4skman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007, 17:573-9. 10.1016\/j.euroneuro.2007.01.005","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.08.016","article-title":"Young women are the most vulnerable to postpartum mental illness: A retrospective cohort study in UK primary care","volume":"277","author":"Swift ER","year":"2020","unstructured":"Swift ER, Pierce M, Hope H, et al.. Young women are the most vulnerable to postpartum mental illness: A retrospective cohort study in UK primary care. J Affect Disord. 2020, 277:218-24. 10.1016\/j.jad.2020.08.016","journal-title":"J Affect Disord"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S219962","article-title":"Changes in plasma NPY, IL-1\u03b2 and hypocretin in people who died by suicide","volume":"15","author":"Lu J","year":"2019","unstructured":"Lu J, Li S, Li H, et al.. Changes in plasma NPY, IL-1\u03b2 and hypocretin in people who died by suicide. Neuropsychiatr Dis Treat. 2019, 15:2893-900. 10.2147\/NDT.S219962","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.676336","article-title":"Increased hypocretin (orexin) plasma level in depression, bipolar disorder patients","volume":"12","author":"Li H","year":"2021","unstructured":"Li H, Lu J, Li S, et al.. Increased hypocretin (orexin) plasma level in depression, bipolar disorder patients. Front Psychiatry. 2021, 12:676336. 10.3389\/fpsyt.2021.676336","journal-title":"Front Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-1781(02)00032-X","article-title":"CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture","volume":"110","author":"Nishino S","year":"2002","unstructured":"Nishino S, Ripley B, Mignot E, et al.. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002, 110:1-7.","journal-title":"Psychiatry Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally J","year":"2015","unstructured":"Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review. Br Med Bull. 2015, 114:169-79. 10.1093\/bmb\/ldv017","journal-title":"Br Med Bull"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2017.09.003","article-title":"Nitric oxide signaling in neurodegeneration and cell death","volume":"82","author":"Dawson TM","year":"2018","unstructured":"Dawson TM, Dawson VL. Nitric oxide signaling in neurodegeneration and cell death. Adv Pharmacol. 2018, 82:57-83. 10.1016\/bs.apha.2017.09.003","journal-title":"Adv Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231225610","article-title":"Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study","volume":"38","author":"Chen PY","year":"2024","unstructured":"Chen PY, Chiu CC, Chang CK, et al.. Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study. J Psychopharmacol. 2024, 38:258-67. 10.1177\/02698811231225610","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2014.12.012","article-title":"Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms","volume":"53","author":"Chien YL","year":"2015","unstructured":"Chien YL, Liu CM, Shan JC, et al.. Elevated plasma orexin A levels in a subgroup of patients with schizophrenia associated with fewer negative and disorganized symptoms. Psychoneuroendocrinology. 2015, 53:1-9. 10.1016\/j.psyneuen.2014.12.012","journal-title":"Psychoneuroendocrinology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.879414","article-title":"Plasma orexin-A levels in patients with schizophrenia: A systematic review and meta-analysis","volume":"13","author":"Li S","year":"2022","unstructured":"Li S, Zhang R, Hu S, Lai J. Plasma orexin-A levels in patients with schizophrenia: A systematic review and meta-analysis. Front Psychiatry. 2022, 13:879414. 10.3389\/fpsyt.2022.879414","journal-title":"Front Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/02763869.2019.1588072","article-title":"PROSPERO: An international register of systematic review protocols","volume":"38","author":"Schiavo JH","year":"2019","unstructured":"Schiavo JH. PROSPERO: An international register of systematic review protocols. Med Ref Serv Q. 2019, 38:171-80. 10.1080\/02763869.2019.1588072","journal-title":"Med Ref Serv Q"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2018.345","article-title":"The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review","volume":"106","author":"Eriksen MB","year":"2018","unstructured":"Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018, 106:420-31. 10.5195\/jmla.2018.345","journal-title":"J Med Libr Assoc"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani M","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016, 5:210. 10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim K","year":"2003","unstructured":"Slim K, Nini E, Forestier D, et al.. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003, 73:712-6. 10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbab042","article-title":"Changes of hypocretin (orexin) system in schizophrenia: from plasma to brain","volume":"47","author":"Lu J","year":"2021","unstructured":"Lu J, Huang ML, Li JH, et al.. Changes of hypocretin (orexin) system in schizophrenia: from plasma to brain. Schizophr Bull. 2021, 47:1310-9. 10.1093\/schbul\/sbab042","journal-title":"Schizophr Bull"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1180720","article-title":"Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function","volume":"14","author":"Yu H","year":"2023","unstructured":"Yu H, Ni P, Zhao L, et al.. Decreased plasma neuropeptides in first-episode schizophrenia, bipolar disorder, major depressive disorder: associations with clinical symptoms and cognitive function. Front Psychiatry. 2023, 14:1180720. 10.3389\/fpsyt.2023.1180720","journal-title":"Front Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyy075","article-title":"Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics","volume":"22","author":"Chen PY","year":"2019","unstructured":"Chen PY, Chen CH, Chang CK, et al.. Orexin-A levels in relation to the risk of metabolic syndrome in patients with schizophrenia taking antipsychotics. Int J Neuropsychopharmacol. 2019, 22:28-36. 10.1093\/ijnp\/pyy075","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2015.11.013","article-title":"Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients","volume":"64","author":"Sun HQ","year":"2016","unstructured":"Sun HQ, Li SX, Chen FB, et al.. Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients. Psychoneuroendocrinology. 2016, 64:108-16. 10.1016\/j.psyneuen.2015.11.013","journal-title":"Psychoneuroendocrinology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283377850","article-title":"Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis","volume":"25","author":"Basoglu C","year":"2010","unstructured":"Basoglu C, Oner O, Gunes C, et al.. Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis. Int Clin Psychopharmacol. 2010, 25:165-71. 10.1097\/YIC.0b013e3283377850","journal-title":"Int Clin Psychopharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122581","article-title":"A direct estrogenic involvement in the expression of human hypocretin","volume":"344","author":"Li H","year":"2024","unstructured":"Li H, Chen X, Dong J, et al.. A direct estrogenic involvement in the expression of human hypocretin. Life Sci. 2024, 344:122581. 10.1016\/j.lfs.2024.122581","journal-title":"Life Sci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.06.060","article-title":"Association between peripheral orexin A\/B levels and depression with childhood trauma","volume":"340","author":"Wang L","year":"2023","unstructured":"Wang L, Wang R, Song M, et al.. Association between peripheral orexin A\/B levels and depression with childhood trauma. J Affect Disord. 2023, 340:592-7. 10.1016\/j.jad.2023.06.060","journal-title":"J Affect Disord"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/gbb.12707","article-title":"Orexin deficiency modulates cognitive flexibility in a sex-dependent manner","volume":"20","author":"Durairaja A","year":"2021","unstructured":"Durairaja A, Fendt M. Orexin deficiency modulates cognitive flexibility in a sex-dependent manner. Genes Brain Behav. 2021, 20:e12707. 10.1111\/gbb.12707","journal-title":"Genes Brain Behav"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.12.008","article-title":"Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials","volume":"372","author":"Meshkat S","year":"2025","unstructured":"Meshkat S, Kwan AT, Le GH, et al.. Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials. J Affect Disord. 2025, 372:409-19. 10.1016\/j.jad.2024.12.008","journal-title":"J Affect Disord"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.11613\/BM.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31","author":"Serdar CC","year":"2021","unstructured":"Serdar CC, Cihan M, Y\u00fccel D, Serdar MA. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb). 2021, 31:010502. 10.11613\/BM.2021.010502","journal-title":"Biochem Med (Zagreb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444886-circulating-orexin-a-levels-in-patients-with-schizophrenia-bipolar-disorder-and-major-depressive-disorder-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T15:17:23Z","timestamp":1768403843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444886-circulating-orexin-a-levels-in-patients-with-schizophrenia-bipolar-disorder-and-major-depressive-disorder-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.101525","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,14]]}}}